XPOVIO (selinexor) for the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

XPOVIO (selinexor) is the first and only FDA-approved nuclear export inhibitor used for both multiple myeloma and DLBCL. Credit: Karyopharm Therapeutics Inc.



  • XPOVIO (selinexor)
  • XPOVIO (selinexor)
  • XPOVIO (selinexor)